SynAct Pharma AB develops medicines for acute impairment in inflammatory diseases. The company’s drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis – a form of acute arthritis that affects approximately 30 percent of patients suffering from psoriasis. Preclinical studies show that the AP1189 has a unique ability to both reduce inflammation and accelerate the euthanasia, which is expected to reduce joint damage that may occur after acute forests of inflammation of the joints. AP1189 has the potential to be given in tablet form once a day. Results from a Phase I clinical trial are expected to be available in Q2 2018.
What have been the milestones so far in your company development?
We have in a relative short period of time moved our lead project from preclinical stage into Phase ll and expect to have the first results of part one during first half of 2020.
What are your most important markets, segments and customers?
Synact will upon positive phase ll data out license the project to either big pharma or big biotech companies in order for them to perform the phase lll studies and bring the compound to the market. We trust that there is a strong interest in the market for such projects and have a track record of completing such deals
Where do you see the company five years from now?
We are quit confident that we with positive data from the studies will be able to complete a deal – by doing so we have promised the market to pay back the proceeds. If we should keep part of the money to fuel our other projects is still to early to say but could be an option.
What are your priorities within 2020?
In 2019 we have full focus on completing the financing of the company and have recently managed to establish a very attractive model for the company and for its shareholders. In 2020 focus will be on driving the Phase ll project, get the next project (Nephrotic Syndrome) into Phase ll and continue the business development activity.
Why should one consider adding your company into their portfolio?
Synact will during 2020 develop from a one trick pony with one project into a later stage biotech company with two projects into Phase ll.